• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Celgene Corporation

Celgene Corporation

  1. All
  2. Morningstar Articles
  3. 3rd Party
  4. Investing
  1. Pancreatic Ductal Adenocarcinoma Pipeline Report 2016 - Review of 24 Companies & Drug Profiles - Research and Markets

    Pancreatic Ductal Adenocarcinoma Pipeline Report 2016 - Review of 24 Companies & Drug Profiles - Research and Markets

  2. Global Oligodendroglioma Therapeutics Pipeline Report 2016 - Review of 12 Companies & Drug Profiles - Research and Markets

    Global Oligodendroglioma Therapeutics Pipeline Report 2016 - Review of 12 Companies & Drug Profiles - Research and Markets

  3. Systemic Sclerosis (Scleroderma) Global Clinical Trials Review, H1, 2016 - Analysis, Technologies & Forecasts Report - Key Vendors: Actelion, Novartis, Allergan - Research and Markets

    Systemic Sclerosis (Scleroderma) Global Clinical Trials Review, H1, 2016 - Analysis, Technologies & Forecasts Report - Key Vendors: Actelion, Novartis, Allergan - Research and Markets

  4. Myelodysplastic Syndrome Global Clinical Trials Review, H1, 2016 - Analysis, Technologies & Forecasts Report - Key Vendors: Celgene Corp, Novartis, Sanofi - Research and Markets

    Myelodysplastic Syndrome Global Clinical Trials Review, H1, 2016 - Analysis, Technologies & Forecasts Report - Key Vendors: Celgene Corp, Novartis, Sanofi - Research and Markets

  5. Sarcoidosis Global Clinical Trials Review, H1, 2016 - Research and Markets

    Sarcoidosis Global Clinical Trials Review, H1, 2016 - Research and Markets

  6. Esophageal Cancer - Pipeline Review, H1 2016 - Key Players are Amgen, ImmunoGen & Bayer AG - Research and Markets

    Esophageal Cancer - Pipeline Review, H1 2016 - Key Players are Amgen, ImmunoGen & Bayer AG - Research and Markets

  7. Agios, Celgene Reach Deal to Develop Cancer Immunotherapies

    Agios, Celgene Reach Deal to Develop Cancer Immunotherapies

  8. Will the Election Affect Earnings?

    If Americans sweep Democrats into office, these healthcare proposals could get a shot in the arm. Here’s how they would have an impact on earnings.

  9. Share Repurchase: Potential Signal of Undervaluation and Outperformance

    Celgene's CELG prized drug Revlimid was approved for multiple myeloma in June, and third-quarter results gave us our first look at sales for its use in treating a second form of blood cancer. While Revlimid's multiple myeloma launch was strong and did not appear to cannibalize legacy drug ...

  10. Tuttle Tactical Management Weekly Market Notes

    Tuttle Tactical Management, LLC is an investment adviser registered with the U.S. Securities and Exchange Commission. You should not assume that any discussion or information contained in this letter serves as the receipt of, or as a substitute for, personalized investment advice from Tuttle Tactical Management, LLC. It is published solely for informational purposes and is not to be construed as a solicitation nor does it constitute advice, investment or otherwise. To the extent that a reader has questions regarding the applicability of any specific issue discussed above to his/her individual situation, he/she is encouraged to consult with the professional adviser of his/her choosing. A copy of our written disclosure statement regarding our advisory services and fees is available upon request. Our comments are an expression of opinion. While we believe our statements to be true, they always depend on the reliability of our own credible sources. Past performance is no guarantee of ...

123
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.